Clin2
NCT06205056Possibly a fitRecruiting

HIV vaccine safety and immune response test

Human Immunodeficiency Virus

Treatments studied

Part of Immune system & allergy, Infections clinical trials.

This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
78 people
Ages
18 years to 50 years
Study type
Interventional

Who can take part

  • Be between 18 and 50 years old
  • Be in good general health (no chronic illnesses like diabetes, thyroid disease, or bleeding disorders)
  • Have normal blood counts and liver/kidney function tests
  • Not be pregnant, breastfeeding, or planning pregnancy during the study
  • Agree to use effective contraception (if biologically male or female) and not donate blood or sperm during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07530198Recruiting· Phase 1
HIV DNA vaccine test for people on stable treatment

This study tests a new DNA vaccine (ICVAX) designed to help your immune system better control HIV. You'll receive injections over several months if your HIV is well-controlled with current medications.

Shatin, New Territories
NCT06796686Recruiting· Phase 1
HIV vaccine safety and immune response study for healthy adults

This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.

San Francisco, California
NCT07675629Not yet recruiting· Phase 2
HIV vaccine safety and immune response study

This study tests a new HIV vaccine in healthy, HIV-negative adults to see if it is safe and creates an immune response. The vaccine uses DNA and a protein to try to teach your body to fight HIV.

Boston, Massachusetts
NCT07757802Not yet recruiting· Phase 1
Testing an experimental HIV vaccine for safety in healthy adults

This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.

San Francisco, California
NCT07390474Recruiting· Phase 1
HIV vaccine safety and immune response study for healthy adults

This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.

Atlanta, Georgia
NCT07769983Enrolling by invitation· Phase 1
HIV vaccine study for people on effective treatment

This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.

Bern, Canton of Bern

Hear when a new Human Immunodeficiency Virus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.